ONGLYZA® (saxagliptin)

How do you choose the right DPP-4 inhibitor for your patients with type 2 diabetes?

SAVOR: The Onglyza CV outcomes study

Cardiovascular risk: Baseline characteristics

Baseline vascular risk factors1

Baseline vascular risk factors
Baseline vascular risk factors

CV outcomes trials for other DPP-4 inhibitors are published but are not presented within this document.
If further information is required, please contact the respective pharmaceutical company.

The 16.492 highly comorbid patients on the SAVOR study had a history of documented T2D, an HbA1c level of 6.5-12.0% and either a history of established cardiovascular disease or multiple risk factors for vascular disease1

1. Scirica BM et al. N Engl J Med 2013; 369: 1317-1326.

Baseline characteristics

SAVOR included a broad range of diabetes patients1

Baseline characteristics
Baseline characteristics

The 16,492 highly comorbid patients on the SAVOR study had a history of documented T2D, an HbA1c level of 6.5-12.0% and either a history of established cardiovascular disease or multiple risk factors of vascular disease1

1. Scirica BM et al. N Engl J Med 2013; 369: 1317-1326.

SAVOR: Primary composite endpoint

The primary endpoint was a composite of cardiovascular death; myocardial infarction; or ischaemic stroke1

Primary Composite End-Point
Primary Composite End-Point

1. Scirica BM et al. N Engl J Med 2013; 369; 1317-1326.

SAVOR: Secondary composite endpoint

Secondary composite endpoint: CV death; myocardial infarction; ischaemic stroke; hospitalisation of unstable angina, coronary revascularisation or heart failure1

Secondary composite endpoint
Secondary composite endpoint

An increase in hospitalisation for heart failure (HHF) was observed in the Onglyza group compared to placebo (3.5% vs. 2.8%, respectively p=0.007)

1. Scirica BM et al. N Engl J Med 2013; 360: 1317-1326.